MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02250cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
170322s2016 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.08.05.M.Sc.2016.Ra.D |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ramy Sayed Aboelella Ahmed |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Design and synthesis of thieno[2,3-d]pyrimidine derivatives and their biological evaluation as Antitumor and anti-HIV agents / |
| Statement of responsibility, etc. |
Ramy Sayed Aboelella Ahmed ; Supervised Fatma Abdelfattah Ragab , Sahar Mahmoud Abouseri , Diaa Abdelsamei |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
HIVتصميم و تشييد بعض مشتقات الثيينو (3,2-د)بيريميدين و تقييم فاعليتها البيولوجية كمضادات للأورام فيروس |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Ramy Sayed Aboelella Ahmed , |
| Date of publication, distribution, etc. |
2016 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
127 P. : |
| Other physical details |
charts , facsimiles ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutical Chemistry |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
In a search for new cytotoxic agents with improved anticancer profile, some new thienopyrimidine and thienotriazolopyrimidine derivatives were synthesized. All the synthesized compounds are tested for their in-vitro cytotoxicity against human breast cancer cell line (MCF-7) in which tyrosine kinases are highly expressed. All target compounds are then subjected for further evaluation against receptor tyrosine kinase enzymes; namely, epidermal growth factor receptor (EGFR), (ErbB-2) and vascular endothelial growth factor receptor-2 (VEGFR-2).Compounds in series I were designed to be nonnucleoside reverse transcriptase inhibitors (NNRTIs). Compounds Va-f were assayed for their inhibitory activity against HIV-1 (IIIB strain) and HIV-2 (ROD strain) using nevirapine as a reference inhibitor. They were found to be moderately active against reverse transcriptase |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
EGFR |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
MCF-7 |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Thienotriazolopyrimidine |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Diaa Abdelsamei , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Fatma Abdelfattah Ragab , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Sahar Mahmoud Abouseri , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Enas |
| Reviser |
Cataloger |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
